Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy
Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis. Methods: The clinical...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2021-04-01
|
| Series: | Global & Regional Health Technology Assessment |
| Subjects: | |
| Online Access: | https://journals.aboutscience.eu/index.php/grhta/article/view/2222 |
| _version_ | 1818873006346207232 |
|---|---|
| author | Roberto Ravasio Antonio Costanzo Silvia Antonelli Alessia Maiorino Serena Losi |
| author_facet | Roberto Ravasio Antonio Costanzo Silvia Antonelli Alessia Maiorino Serena Losi |
| author_sort | Roberto Ravasio |
| collection | DOAJ |
| description | Background: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis.
Methods: The clinical efficacy was evaluated in terms of NNT, based on the results of a recent network meta-analysis (NMA) by the Cochrane Database of Systematic Reviews. The NMA investigated many systemic and biological treatments, but this analysis compared only the efficacy of the following IL inhibitors – brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab – for patients with moderate-to-severe plaque psoriasis. Drugs were compared and ranked according to effectiveness considering the PASI (Psoriasis Area and Severity Index) 90 score.
Results: One-hundred and forty trials (51,749 patients) were included in the NMA. Considering the proportion of patients who achieve PASI90, ixekizumab showed the lowest NNT among all comparators (ixekizumab 2.01 [2.46-3.00]; risankizumab 2.05 [2.50-3-05]; guselkumab 2.16 [2.68-3.36]; secukinumab 2.40 [2.90-3.51]; brodalumab 2.61 [3.18-3.88]; ustekinumab 3.44 [4.12-4.95]; tildrakizumab 3.10 [4.15-5.59].
Conclusion: The findings show that ixekizumab is the most effective option (NNT) for the treatment of moderate-to-severe plaque psoriasis. |
| first_indexed | 2024-12-19T12:47:50Z |
| format | Article |
| id | doaj.art-0ee066a17d7f40bc8cb07526059eb545 |
| institution | Directory Open Access Journal |
| issn | 2284-2403 2283-5733 |
| language | English |
| last_indexed | 2024-12-19T12:47:50Z |
| publishDate | 2021-04-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Global & Regional Health Technology Assessment |
| spelling | doaj.art-0ee066a17d7f40bc8cb07526059eb5452022-12-21T20:20:41ZengAboutScience SrlGlobal & Regional Health Technology Assessment2284-24032283-57332021-04-01810.33393/grhta.2021.2222Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in ItalyRoberto Ravasio0Antonio Costanzo1Silvia Antonelli2Alessia Maiorino3Serena Losi4Health Publishing & Services Srl, Milan - ItalyDermatology, Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan and Dermatology, IRCCS Humanitas Research Hospital, Rozzano, Milan - ItalyEli Lilly Italia S.p.A., Sesto Fiorentino - ItalyEli Lilly Italia S.p.A., Sesto Fiorentino - ItalyEli Lilly Italia S.p.A., Sesto Fiorentino - ItalyBackground: Interleukin (IL) inhibitors achieve greater levels of efficacy than older systemic therapies. We calculated the number needed to treat (NNT) of ixekizumab compared with other IL inhibitors approved in Italy for the treatment of moderate-to-severe plaque psoriasis. Methods: The clinical efficacy was evaluated in terms of NNT, based on the results of a recent network meta-analysis (NMA) by the Cochrane Database of Systematic Reviews. The NMA investigated many systemic and biological treatments, but this analysis compared only the efficacy of the following IL inhibitors – brodalumab, guselkumab, ixekizumab, risankizumab, secukinumab, tildrakizumab and ustekinumab – for patients with moderate-to-severe plaque psoriasis. Drugs were compared and ranked according to effectiveness considering the PASI (Psoriasis Area and Severity Index) 90 score. Results: One-hundred and forty trials (51,749 patients) were included in the NMA. Considering the proportion of patients who achieve PASI90, ixekizumab showed the lowest NNT among all comparators (ixekizumab 2.01 [2.46-3.00]; risankizumab 2.05 [2.50-3-05]; guselkumab 2.16 [2.68-3.36]; secukinumab 2.40 [2.90-3.51]; brodalumab 2.61 [3.18-3.88]; ustekinumab 3.44 [4.12-4.95]; tildrakizumab 3.10 [4.15-5.59]. Conclusion: The findings show that ixekizumab is the most effective option (NNT) for the treatment of moderate-to-severe plaque psoriasis.https://journals.aboutscience.eu/index.php/grhta/article/view/2222Interleukin inhibitorIxekizumabNumber needed to treatPlaque psoriasis |
| spellingShingle | Roberto Ravasio Antonio Costanzo Silvia Antonelli Alessia Maiorino Serena Losi Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy Global & Regional Health Technology Assessment Interleukin inhibitor Ixekizumab Number needed to treat Plaque psoriasis |
| title | Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy |
| title_full | Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy |
| title_fullStr | Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy |
| title_full_unstemmed | Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy |
| title_short | Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in Italy |
| title_sort | number needed to treat for interleukin inhibitors approved for the treatment of moderate to severe plaque psoriasis in italy |
| topic | Interleukin inhibitor Ixekizumab Number needed to treat Plaque psoriasis |
| url | https://journals.aboutscience.eu/index.php/grhta/article/view/2222 |
| work_keys_str_mv | AT robertoravasio numberneededtotreatforinterleukininhibitorsapprovedforthetreatmentofmoderatetosevereplaquepsoriasisinitaly AT antoniocostanzo numberneededtotreatforinterleukininhibitorsapprovedforthetreatmentofmoderatetosevereplaquepsoriasisinitaly AT silviaantonelli numberneededtotreatforinterleukininhibitorsapprovedforthetreatmentofmoderatetosevereplaquepsoriasisinitaly AT alessiamaiorino numberneededtotreatforinterleukininhibitorsapprovedforthetreatmentofmoderatetosevereplaquepsoriasisinitaly AT serenalosi numberneededtotreatforinterleukininhibitorsapprovedforthetreatmentofmoderatetosevereplaquepsoriasisinitaly |